Search

Displaying results 4091 - 4100 of 10000 in total
  1. Drug

    CCX915

    go.drugbank.com/drugs/DB05159
    Experimental

    CCX915 is developed by ChemoCentryx which targets the chemokine receptor CCR2 and is in phase 1 of clinical trial for the treatment of Multiple Sclerosis and Neurologic Disorders.

  2. Drug

    Influenza B virus B/Austria/1359417/2021 live (attenuated) antigen

    go.drugbank.com/drugs/DB16902
    Approved

    These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Inactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals.

  3. Drug

    Influenza A virus A/Darwin/6/2021 IVR-227 (H3N2) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB16903
    ApprovedWithdrawn

    These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Inactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals.

  4. Drug

    Influenza B virus B/Singapore/WUH4618/2021 antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB16910
    Approved

    These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Inactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals.

  5. Drug

    Influenza A virus A/Darwin/11/2021 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB16914
    ApprovedWithdrawn

    These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Inactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals.

  6. Drug

    Influenza A virus A/Delaware/55/2019 CVR-45 (H1N1) antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB16915
    ApprovedWithdrawn

    These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Inactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals.

  7. Drug

    Influenza B virus B/Austria/1359417/2021 BVR-26 antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB16919
    ApprovedWithdrawn

    These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Inactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals.

  8. Drug

    Tubercidin

    go.drugbank.com/drugs/DB03172
    Experimental

    An antibiotic purine ribonucleoside that readily substitutes for adenosine in the biological system, but its incorporation into DNA and RNA has an inhibitory effect on the metabolism of these nucleic acids

  9. Drug

    Detomidine

    go.drugbank.com/drugs/DB11556
    InvestigationalVet approved

    Currently, it is only approved by the FDA for use in horses but has been studied for use in other large animals. … Detomidine is an α2-adrenergic agonist that is used as a horse sedative. Normally, it is administered in the salt form, detomidine hydrochloride.

  10. Drug

    Tipifarnib

    go.drugbank.com/drugs/DB04960
    Investigational

    In June 2005, the FDA issued a Not Approvable Letter for Zarnestra. … Tipifarnib (R-115777) is a substance that is being studied in the treatment of acute myeloid leukemia (AML) and other types of cancer.